Contribution of endopeptidase 3.4.24.15 to central neurotensin inactivation

European Journal of Pharmacology

Volumn 334, Issue 1, 1997, Pages 49-53

  Vincent, Bruno ^a   Jiracek, Jirì ^b   Noble, Florence ^c   Loog, Mart ^a   Roques, Bernard ^c   Dive, Vincent ^b   Vincent, Jean Pierre ^a   Checler, Frédéric ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b DIF   (France)

^c CNRS   (France)

Author keywords

Analgesia; Endopeptidase 3.4.24.15; Mouse; Neurotensin; Phosphinic inhibitor

Indexed keywords

ENZYME INHIBITOR; NEUROTENSIN; PROTEINASE; THIMET OLIGOPEPTIDASE;

ANALGESIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT;

ANALGESIA; ANALGESICS; ANIMALS; DRUG SYNERGISM; ENZYME INHIBITORS; MALE; METALLOENDOPEPTIDASES; MICE; NEUROTENSIN; OLIGOPEPTIDES; PAIN MEASUREMENT; RATS; RATS, WISTAR;

EID: 0030800486     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01209-0     Document Type: Article

References (29)

1. Al-Rhodan N.R.F., Richelson E., Gilbert J., McCormick D.J., Kanba K.S., Pfenning M.A., Nelson A., Larson E.W., Yaksh T.L. Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Res. 557:1991;227-235.
2. Barelli H., Dive V., Yiotakis A., Vincent J.P., Checler F. Potent inhibition of endopeptidase 24.16 and endopeptidase 24.15 by the phosphonamide peptide N-(phenylethylphosphonyl)-Gly-L-Pro-L-aminohexanoic acid. Biochem. J. 287:1992;621-625.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-259.
4. Camargo A.C.M., Almeida M.L.C., Emson P.C. Involvement of endo-oligopeptidases A and B in the degradation of neurotensin by rabbit brain. J. Neurochem. 42:1984;1758-1761.
5. Cardozo C., Orlowski M. Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin-converting enzyme. Peptides. 14:1993;1259-1262.
6. Chappell M.C., Welches W.R., Brosnihan K.B., Ferrario C.M. Inhibition of angiotensin-converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-Phenylpropyl-Alanyl-Alanyl-phenylalanyl-p-aminobenzoate. Peptides. 13:1992;943-946.
7. Checler, F., 1993. Neuropeptide-degrading peptidases. In: Nagatsu, T., Parvez, H., Naoi, M., Parvez, S. (Eds.), Methods in Neurotransmitter and Neuropeptide Research. Part 2. vol. 11. Elsevier Science Publishers, Amsterdam, pp. 375-418.
8. 9 peptide bond by a metalloendopeptidase. J. Neurochem. 45:1985;1509-1513.
9. Checler F., Mazella J., Kitabgi P., Vincent J.P. High affinity receptor sites and rapid proteolytic inactivation of neurotensin in primary cultured neurons. J. Neurochem. 47:1986;1742-1748.
10. Checler F., Barelli H., Kitabgi P., Vincent J.P. Neurotensin metabolism in various tissues from central and peripheral origins. Ubiquitous involvement of a novel neurotensin degrading metalloendopeptidase. Biochimie. 70:1988;75-82.
11. Checler F., Dauch P., Masuo Y., Vincent J.P. Neurotensin and neuromedin N are differently metabolized in ventral tegmental area and nucleus accumbens. J. Neurochem. 56:1991;1320-1328.
12. Checler, F., Dauch, P., Barelli, H., Dive, V., Masuo, Y., Vincent, B., Vincent, J.P., 1995. Identification and distribution of endopeptidase 24.16 in the central nervous system. In: Conn., M.P. (Ed), Methods in Neurosciences, vol. 23. Academic Press., pp. 363-382.
13. Chu T.G., Orlowski M. Active site directed N-carboxymethyl peptide inhibitors of a soluble metalloendopeptidase from rat brain. Biochemistry. 23:1984;3598-3603.
14. Clineschmidt B.V., MacGuffin J.V., Bunting P.B. Neurotensin: Antinocisponsive action in rodents. Eur. J. Pharmacol. 54:1979;129-139.
15. Coquerel A., Dubuc I., Kitabgi P., Costentin P. Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin N. Neurochem. Int. 12:1988;361-366.
16. Dauch P., Vincent J.P., Checler F. Molecular cloning and expression of rat brain endopeptidase 3.4.24.16. J. Biol. Chem. 270:1995;27266-27271.
17. Davis T.P., Gillespie T.J., Konings P.N.M. Specificity of neurotensin metabolism by regional rat brain slices. J. Neurochem. 58:1992;608-617.
18. Eddy N.B., Leimblach D. Synthetic analgesics (II): Dithienylbutenyl and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107:1953;385-393.
19. Jiràcek J., Yiotakis A., Vincent B., Lecoq A., Nicolaou A., Checler F., Dive V. Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24.15 using combinatorial chemistry. J. Biol. Chem. 270:1995;21701-21706.
20. Jiràcek J., Yiotakis A., Vincent B., Checler F., Dive V. Development of the first potent and selective inhibitor iof the zinc-endopeptidase 3.4.24.16 using a systematic approach based on combinatorial chemistry of phosphinic peptides. J. Biol. Chem. 271:1996;19606-19611.
21. Kitabgi P., Dubuc I., Nouel D., Costentin J., Cuber J.-C., Fulcrand H., Doulut S., Rodriguez M., Martinez J. Effects of thiorphan, bestatin and a novel metallopeptidase inhibitor JMV 390-1 on the recovery of neurotensin and neuromedin N released from mouse hypothalamus. Neurosci. Lett. 142:1992;200-204.
22. Knight G., Barrett A.J. Structure/function relationships in the inhibition of thimet oligopeptidase by carboxyphenylpropyl-peptides. FEBS Lett. 294:1991;183-186.
23. Lew R.A., Tomoda F., Evans R.G., Lakat L., Boublik J.H., Pipolo L.A., Smith A.I. Synthetic inhibitors of endopeptidase EC 3.4.24.15: Potency and stability in vitro and in vivo. Br. J. Pharmacol. 118:1996;1269-1277.
24. Orlowski M., Michaud C., Molineaux C.J. Substrate-related potent inhibitors of brain metalloendopeptidase. Biochemistry. 27:1988;597-602.
25. Schmidt C., Peyroux J., Noble F., Fournié-Zaluski M.C., Roques B.P. Analgesic responses elicited by endogenous enkephalins (protected by mixed peptidase inhibitors) in a variety of morphine-sensitive noxious tests. Eur. J. Pharmacol. 192:1991;253-262.
26. Vincent B., Dive V., Yiotakis A., Smadja C., Maldonado R., Vincent J.P., Checler F. Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: Effect on neurotensin degradation in vitro and in vivo. Br. J. Pharmacol. 115:1995;1053-1063.
27. Vincent B., Jiracek J., Noble F., Loog M., Roques B., Dive V., Vincent J.P., Checler F. A novel selective and potent phosphinic peptide inhibitor of endopeptidase 3.4.24.16: Effect on neurotensin-induced analgesia and neuronal inactivation. Br. J. Pharmacol. 121:1997;705-710.
28. Williams C.H., Yamamoto T., Walsh D., Allsop D. Endopeptidase 3.4.24.11 converts N-1(R,S)-carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme. Biochem. J. 294:1993;681-684.
29. Yiotakis A., Vassilou S., Jiracek J., Dive V. Protection of hydroxyphosphinyl function of phosphinic dipeptides by adamantyl. Application to the solid-phase synthesis of phosphinic peptides. J. Org. Chem. 61:1996;6601-6605.